Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients

The deletion of exons 9 to 12 of BRCA1 (9–12 del BRCA1) is considered a founder mutation in the Mexican population. We evaluate the usefulness of the target detection of 9–12 del BRCA1 as the first molecular diagnostic strategy in patients with Hereditary Breast and Ovarian Cancer (HBOC). We perform...

Descripción completa

Detalles Bibliográficos
Autores principales: Fragoso-Ontiveros, Veronica, Velázquez-Aragón, Jose Antonio, Nuñez-Martínez, Paulina Maria, de la Luz Mejía-Aguayo, Maria, Vidal-Millán, Silvia, Pedroza-Torres, Abraham, Sánchez-Contreras, Yuliana, Ramírez-Otero, Miguel Angel, Muñiz-Mendoza, Rodolfo, Domínguez-Ortíz, Julieta, Wegman-Ostrosky, Talia, Bargalló-Rocha, Juan Enrique, Gallardo-Rincón, Dolores, Reynoso-Noveron, Nancy, Arriaga-Canon, Cristian, Meneses-García, Abelardo, Herrera-Montalvo, Luis Alonso, Alvarez-Gomez, Rosa Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756553/
https://www.ncbi.nlm.nih.gov/pubmed/31545835
http://dx.doi.org/10.1371/journal.pone.0222709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756553/
https://www.ncbi.nlm.nih.gov/pubmed/31545835
http://dx.doi.org/10.1371/journal.pone.0222709

Ejemplares similares